Neurocrine Biosciences | NBIX - Gross Profit On Sales


Neurocrine Biosciences reported $800.7M in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
AbbVie USD 14.39B 1.85B Jun/2026
Acadia Pharmaceuticals USD 279.64M 36.37M Jun/2026
Agios Pharmaceuticals USD 19.43M 1.34M Mar/2026
ALKERMES USD 375.31M 43.98M Jun/2026
Alnylam Pharmaceuticals USD 992.69M 167.68M Jun/2026
Amgen USD 5.87B 1.02B Mar/2026
Biogen USD 2.12B 307M Jun/2026
BioMarin Pharmaceutical USD 713.42M 142.21M Jun/2026
Cytokinetics USD 23.03M 3.84M Jun/2026
Enanta Pharmaceuticals -22.29M 23.75M Dec/2024
Exelixis USD 590.86M 18.68M Mar/2026
Gilead Sciences USD 6.8B 1.29B Jun/2026
Halozyme Therapeutics USD 297.47M 75.53M Mar/2026
Incyte USD 1.57B 400.89M Jun/2026
Ionis Pharmaceuticals USD 265M 22M Jun/2026
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Neurocrine Biosciences USD 800.7M 12.8M Mar/2026
Pfizer USD -248M 11.29B Jun/2026
Prothena USD 51.08M 51.06M Mar/2026
Regeneron Pharmaceuticals USD 3.71B 778.2M Jun/2026
Repligen USD 110.04M 1.75M Jun/2026
Rigel Pharmaceuticals USD 28.49M 7.01M Jun/2024
Sarepta Therapeutics USD 251.15M 370.2M Jun/2026
Teva Pharmaceutical Industries USD 2.15B 45M Jun/2026
Ultragenyx Pharmaceutical USD 180M 74M Jun/2026
Vertex Pharmaceuticals USD 2.84B 242.4M Jun/2026